A 20-year-old man presented with a 3-week history of nodular lesions of the scalp (Fig. 1a, b) , which progressed despite topical treatment with glucocorticosteroids. He also had cervical lymphadenopathy and complained of headache, fatigue and blurred vision. His blood count demonstrated a pronounced leukocytosis of 114/nL with 55% lymphoblasts, slight thrombocytopenia (83/nL) and a normal hemoglobin level (150 g/L). The serum levels of lactate dehydrogenase (LDH 6402 U/l), creatinine (1.94 mg/dl) and uric acid (16.1 mg/dl) were significantly elevated, and there were laboratory findings indicative of disseminated intravascular coagulation (INR 1.69, D-dimer 5053 lg/L).
A 20-year-old man presented with a 3-week history of nodular lesions of the scalp (Fig. 1a, b) , which progressed despite topical treatment with glucocorticosteroids. He also had cervical lymphadenopathy and complained of headache, fatigue and blurred vision. His blood count demonstrated a pronounced leukocytosis of 114/nL with 55% lymphoblasts, slight thrombocytopenia (83/nL) and a normal hemoglobin level (150 g/L). The serum levels of lactate dehydrogenase (LDH 6402 U/l), creatinine (1.94 mg/dl) and uric acid (16.1 mg/dl) were significantly elevated, and there were laboratory findings indicative of disseminated intravascular coagulation (INR 1.69, D-dimer 5053 lg/L). Microscopic and flow cytometric analyses of blood and bone marrow were consistent with acute lymphoblastic leukemia (ALL) of mature T cell type. The chest X-ray revealed a mediastinal mass (Fig. 1c) . Treatment was started with oral dexamethasone at a dose of 10 mg/m 2 per day (d1-5) and cyclophosphamid 200 mg/m 2 per day (d3-5) (German Multicenter ALL Study Group; study protocol GMALL 07/2003). As early as 3 days after the first dose, the skin lesions and the mediastinal mass regressed completely (Fig. 1d) , paralleled by a dramatic improvement of the leukocyte count (11.83/nl) and the serum values of LDH (1179 U/l) and creatinine (1.18 mg/dl). A mediastinal mass is present in over half of patients with newly diagnosed ALL of T cell origin, but skin lesions are rare.
